Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

92 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Actionability of on-target ALK Resistance Mutations in Patients With Non-Small Cell Lung Cancer: Local Experience and Review of the Literature.
Koopman B, Groen HJM, Schuuring E, Hiltermann TJN, Timens W, den Dunnen WFA, van den Berg A, Ter Elst A, van Kruchten M, Kluiver JL, Hiddinga BI, Hijmering-Kappelle LBM, Groves MR, Vilacha JF, van Kempen LC, van der Wekken AJ. Koopman B, et al. Among authors: hiltermann tjn. Clin Lung Cancer. 2022 Mar;23(2):e104-e115. doi: 10.1016/j.cllc.2021.06.011. Epub 2021 Jul 3. Clin Lung Cancer. 2022. PMID: 34325996 Free article. Review.
Targeting apoptosis pathways in lung cancer.
Pore MM, Hiltermann TJ, Kruyt FA. Pore MM, et al. Cancer Lett. 2013 May 28;332(2):359-68. doi: 10.1016/j.canlet.2010.09.012. Epub 2010 Oct 25. Cancer Lett. 2013. PMID: 20974517 Review.
Randomized, placebo-controlled phase III study of docetaxel plus carboplatin with celecoxib and cyclooxygenase-2 expression as a biomarker for patients with advanced non-small-cell lung cancer: the NVALT-4 study.
Groen HJ, Sietsma H, Vincent A, Hochstenbag MM, van Putten JW, van den Berg A, Dalesio O, Biesma B, Smit HJ, Termeer A, Hiltermann TJ, van den Borne BE, Schramel FM. Groen HJ, et al. J Clin Oncol. 2011 Nov 10;29(32):4320-6. doi: 10.1200/JCO.2011.35.5214. Epub 2011 Oct 11. J Clin Oncol. 2011. PMID: 21990410 Clinical Trial.
Moving forward with circulating tumor cells and lung cancer.
Hiltermann TJ, van der Wekken AJ, Groen HJ. Hiltermann TJ, et al. J Thorac Dis. 2012 Oct;4(5):440-1. doi: 10.3978/j.issn.2072-1439.2012.08.08. J Thorac Dis. 2012. PMID: 23050099 Free PMC article. No abstract available.
The detection of EpCAM(+) and EpCAM(-) circulating tumor cells.
de Wit S, van Dalum G, Lenferink AT, Tibbe AG, Hiltermann TJ, Groen HJ, van Rijn CJ, Terstappen LW. de Wit S, et al. Sci Rep. 2015 Jul 17;5:12270. doi: 10.1038/srep12270. Sci Rep. 2015. PMID: 26184843 Free PMC article.
First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer.
Carbone DP, Reck M, Paz-Ares L, Creelan B, Horn L, Steins M, Felip E, van den Heuvel MM, Ciuleanu TE, Badin F, Ready N, Hiltermann TJN, Nair S, Juergens R, Peters S, Minenza E, Wrangle JM, Rodriguez-Abreu D, Borghaei H, Blumenschein GR Jr, Villaruz LC, Havel L, Krejci J, Corral Jaime J, Chang H, Geese WJ, Bhagavatheeswaran P, Chen AC, Socinski MA; CheckMate 026 Investigators. Carbone DP, et al. Among authors: hiltermann tjn. N Engl J Med. 2017 Jun 22;376(25):2415-2426. doi: 10.1056/NEJMoa1613493. N Engl J Med. 2017. PMID: 28636851 Free PMC article.
92 results